Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fujimasa Tada

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Open Medicine (Warsaw, Poland)|September 21, 2018
Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver DiseaseTeruki Miyake, Sakiko Yoshida, Shinya Furukawa, et al.
Cancers|November 14, 2023
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by EraYoshiko Nakamura, Masashi Hirooka, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2025
Impact of muscle volume changes following atezolizumab-bevacizumab therapy in patients with unresectable hepatocellular carcinomaHironori Ochi, Joji Tani, Tetsu Tomonari, et al.
Journal of Gastroenterology and Hepatology|April 11, 2024
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agentsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 1, 2022
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world dataShigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, et al.
BMC Cancer|June 15, 2021
AFP and eGFR are related to early and late recurrence of HCC following antiviral therapyTakao Watanabe, Yoshio Tokumoto, Kouji Joko, et al.
Journal of Gastroenterology and Hepatology|May 27, 2025
Comparison of Surgical Resection and Radiofrequency Ablation for Early-Stage HCC Patients With Child-Pugh Class BTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
European Journal of Gastroenterology & Hepatology|June 27, 2025
Identification of high-risk group for diabetes-associated hepatocellular carcinoma using noninvasive test for liver fibrosisKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 9, 2026
Effect of Disease Extent on Leucine-Rich α2-Glycoprotein as a Marker for Endoscopic Mucosal Healing in Patients With Ulcerative ColitisShogo Kitahata, Mai Saito, Yuka Kimura, et al.
Oncology|March 30, 2025
Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab TherapyKhanh Van Nguyen, Kosuke Matsui, Hisashi Kosaka, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Open Medicine (Warsaw, Poland)|September 21, 2018
Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver DiseaseTeruki Miyake, Sakiko Yoshida, Shinya Furukawa, et al.
Cancers|November 14, 2023
Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by EraYoshiko Nakamura, Masashi Hirooka, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 7, 2025
Impact of muscle volume changes following atezolizumab-bevacizumab therapy in patients with unresectable hepatocellular carcinomaHironori Ochi, Joji Tani, Tetsu Tomonari, et al.
Journal of Gastroenterology and Hepatology|April 11, 2024
Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agentsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 1, 2022
Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real-world dataShigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, et al.
BMC Cancer|June 15, 2021
AFP and eGFR are related to early and late recurrence of HCC following antiviral therapyTakao Watanabe, Yoshio Tokumoto, Kouji Joko, et al.
Journal of Gastroenterology and Hepatology|May 27, 2025
Comparison of Surgical Resection and Radiofrequency Ablation for Early-Stage HCC Patients With Child-Pugh Class BTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
European Journal of Gastroenterology & Hepatology|June 27, 2025
Identification of high-risk group for diabetes-associated hepatocellular carcinoma using noninvasive test for liver fibrosisKazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 9, 2026
Effect of Disease Extent on Leucine-Rich α2-Glycoprotein as a Marker for Endoscopic Mucosal Healing in Patients With Ulcerative ColitisShogo Kitahata, Mai Saito, Yuka Kimura, et al.
Oncology|March 30, 2025
Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab TherapyKhanh Van Nguyen, Kosuke Matsui, Hisashi Kosaka, et al.
Pageof 12